Javascript must be enabled to continue!
Naltrexone may block euphoria-like placebo effect
View through CrossRef
Naltrexone is a first-line treatment for alcohol use disorders in North America and Europe. It was prescribed to a 63-year-old patient in order to help control amounts of alcohol consumed per drinking occasion. The patient experienced a paradoxical, but consistent side effect of feeling inebriated each time he took naltrexone. In order to investigate this phenomenon we administered naltrexone and a placebo in a randomised double-blind fashion. The patient exhibited a ‘high-like’ response to all placebo capsules and a decrease in the subjectively perceived euphoria shortly after ingestion of naltrexone. Given that this placebo effect could be mediated via opioid receptors we suggest that this case illustrates the ability of naltrexone to eliminate the placebo effect. This feature of naltrexone, upon further investigation, might be used in randomised clinical trials in addition to or as an alternative to a placebo.
Title: Naltrexone may block euphoria-like placebo effect
Description:
Naltrexone is a first-line treatment for alcohol use disorders in North America and Europe.
It was prescribed to a 63-year-old patient in order to help control amounts of alcohol consumed per drinking occasion.
The patient experienced a paradoxical, but consistent side effect of feeling inebriated each time he took naltrexone.
In order to investigate this phenomenon we administered naltrexone and a placebo in a randomised double-blind fashion.
The patient exhibited a ‘high-like’ response to all placebo capsules and a decrease in the subjectively perceived euphoria shortly after ingestion of naltrexone.
Given that this placebo effect could be mediated via opioid receptors we suggest that this case illustrates the ability of naltrexone to eliminate the placebo effect.
This feature of naltrexone, upon further investigation, might be used in randomised clinical trials in addition to or as an alternative to a placebo.
Related Results
Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence
Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence
Background and ObjectivesWe tested long‐acting injectable depot naltrexone for its tolerability, pharmacokinetics, and safety in Phase I.MethodsThe Phase I trial enrolled 36 health...
Naltrexone Pharmacogenetics in Alcohol-dependent Patients
Naltrexone Pharmacogenetics in Alcohol-dependent Patients
<p>Naltrexone is an opioid receptor antagonist, approved by the Food and Drug Administration (FDA) for alcohol addiction, on the basis of two double-blind, placebo-controlled...
Effects of Carbamazepine, AF‐CX 921, and AF‐CX 1325 on Epileptic Discharges and Seizures in Hippocampally Kindled Rats
Effects of Carbamazepine, AF‐CX 921, and AF‐CX 1325 on Epileptic Discharges and Seizures in Hippocampally Kindled Rats
Summary: In nine hippocampally kindled rats (5 normal and 4 microcephalic) a comparative study of the antiepileptic effects of carbamazepine, and AF‐CX 921 [(E)‐2‐[(α‐amino)‐pheny...
Evaluating the Feasibility of Using Historical Placebo Control in Osteoarthritis Trials
Evaluating the Feasibility of Using Historical Placebo Control in Osteoarthritis Trials
Background/Objectives: Randomized controlled trials (RCTs) are the gold standard for evaluating treatment efficacy, yet recruitment and retention remain challenging, particularly w...
Anti-obesity Medication (Naltrexon/Bupropion) in Obesity Management: Single-Centre Early Experience
Anti-obesity Medication (Naltrexon/Bupropion) in Obesity Management: Single-Centre Early Experience
Background: Naltrexone/bupropion is a recently approved antiobesity medication in Malaysia. We aimed to determine the 12-week outcomes of naltrexone/bupropion as an antiobesity med...
Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature
Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature
Background: The introduction of newly formulated extended release (ER) morphine with sequestered naltrexone (Embeda) has provided another treatment option for moderate to severe pe...
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Radical prostatectomy is the most commonly performed treatment option for localised prostate cancer. In the last decades the surgical technique has been improved and modified in or...
Systematic review and meta-analysis of opioid antagonists for smoking cessation
Systematic review and meta-analysis of opioid antagonists for smoking cessation
Objectives
This meta-analysis sought to evaluate the efficacy of opioid antagonists in promoting long-term smoking cessation. Post-treatment abstinence was exam...

